Moderna announced IND Submitted to FDA for phase 2 study of mRNA accine (mRNA-1273) against novel Coronavirus
On Apr. 27, 2020, Moderna announced it has submitted an Investigational New Drug application to the FDA for…
Diffusion Pharma announced pre-IND submission to FDA of design for TSC trials to treat Acute Respiratory Distress Syndrome in COVID-19
On Apr. 27, 2020, Diffusion Pharmaceuticals announced the pre-IND submission to the FDA of a planned clinical program…
FDA warned of ‘Off-Label’ use of antimalarial drugs hydroxychloroquine and chloroquine to treat COVID-19 patients
On Apr. 24, 2020 the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication regarding known…
ViralClear submits investigational New Drug Application to FDA for phase II clinical trials for merimepodib
On Apr. 24, 2020, BioSig Technologies announced that subsidiary ViralClear had submitted an Investigational New Drug (IND) application…
Baxter obtained FDA Emergency Use Authorization for Oxiris blood purification filter for COVID-19 treatment
On Apr. 23, 2020, Baxter announced it had received emergency use authorization (EUA) from the FDA for the…
The FDA issued an emergency use authorization (EUA) for the Philips Medizin Systeme Boeblingen
On Apr. 22, 2020, the FDA issued an emergency use authorization (EUA) for the Philips Medizin Systeme Boeblingen…
Caladrius Biosciences planned to assess CLBS119 cell therapy for repair of COVID-19 induced lung damage
On Apr. 23, 2020, Caladrius Biosciences announced the FDA has authorized its investigational new drug application for the…
FDA approved new therapy for triple negative breast cancer that has spread, not responded to other treatments
On Apr. 22, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab…
LivaNova permitted to modify cardiopulmonary products’ indications for use to include ECMO therapy to address COVID-19
On Apr. 22, 2020, LivaNova announced that several of its cardiopulmonary products are now permitted to be used…
The FDA approved new therapy for triple negative breast cancer
On Apr. 22, 2020, the FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy), developed by Immunomedics, for the…
Quidel’s Lyra direct SARS-CoV-2 assay submitted for Emergency Use Authorization for molecular detection of COVID-19
On Apr. 22, 2020, Quidel announced it has applied for an Emergency Use Authorization (EUA) for the Lyraï¾®…
FDA granted ALung Emergency Use Authorization to Hemolung Respiratory Assist System for treatment of COVID-19
On Apr. 22, 2020, ALung Technologies announced the U.S. Food and Drug Administration (FDA) granted the Company Emergency…
FDA approved IMBRUVICA (ibrutinib) plus Rituximab for ttreatment of patients with CLL
On Apr. 21, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced U.S. Food and Drug Administration…
Adamis Pharma announced production of additional drugs by its US compounding subsidiary to aid in the COVID-19 pandemic
On Apr. 21, 2020, Adamis Pharma announced that its wholly owned drug outsourcing facility, US Compounding (USC), has…
aTyr Pharma announced phase 2 study of ATYR1923 in COVID-19 patients with severe respiratory complications
On Apr. 21, 2020, aTyr Pharma announced the FDA has accepted its Investigational New Drug application to evaluate…
ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials
On Apr. 21, 2020, BioSig Technologies announced that subsidiary ViralClear Pharmaceuticals, had submitted an application for Vicromax(tm) (merimepodib,…
LabCorp COVID-19 at-home test kit received FDA Emergency Use Authorization
On Apr. 21, 2020, LabCorpï¾® announced it has received an Emergency Use Authorization (EUA) from the FDA. The…
Biotechnology | COVID-19 | Diagnostics | FDA | Therapeutics
Todos Medical announced FDA Emergency Use Authorization allowed for Gnomegen COVID-19 PCR test kits
On Apr. 21, 2020, Todos Medical announced that Gnomegen has received Emergency Use Authorization from the FDA for…
Biotechnology | COVID-19 | Disease | FDA | Life Science News | Therapeutics
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients
On Apr. 20, 2020, Novartis has reached an agreement with the FDA to proceed with a Phase III…
Alexion announced plans to initiate phase 3 study of ULTOMIRISï¾® (ravulizumab-cwvz) in hospitalized patients with severe COVID-19
On Apr. 20, 2020, Alexion announced plans to initiate a global Phase 3 study to investigate ULTOMIRISï¾® (ravulizumab-cwvz)…
Screening of 11,552 compounds identified Innovation Pharma’s Brilacidin as promising Potential inhibitors of novel Coronavirus COVID-19
On Apr. 20, 2020, Innovation Pharma reported that based on molecular screening of 11,552 compounds comprising already FDA-approved…
Atossa Therapeutics submitted Clinical Investigation approval to FDA for launch of COVID-19 HOPE study
On Apr. 20, 2020, Atossa Therapeutics announced that it had applied to the FDA for approval to commence…
FDA approved first new drug under international collaboration for patients with HER2-positive metastatic breast cancer
On Apr. 17, 2020, as part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved Seagen’s…
FDA granted ExThera’s Seraph-100 blood filter Emergency Use Authorization for treatment of COVID-19 after promising results in europe and U.S.
On Apr. 17, 2020, after promising COVID-19 treatments in Germany, France, Italy, Spain and the U.S,, ExThera Medical’s…
SeaGen announced FDA approval of TUKYSA (tucatinib) for people with advanced metastatic HER2-positive breast cancer
On Apr. 17, 2020, Seagen announced the FDA granted approval to TUKYSA (tucatinib) tablets in combination with trastuzumab…
Dynavax and Sinovac announced collaboration to develop a Coronavirus (COVID-19) vaccine
On Apr. 16, 2020, Dynavax and Sinovac Biotech, a leading provider of biopharmaceutical products in China, announced a…
FDA accepted for Priority Review Biologics License Application for REGN-EB3 to treat Ebola
On Apr. 16, 2020, Regeneron announced the FDA has accepted for Priority Review a new Biologics License Application…
Atossa Therapeutics launched COVID-19 HOPE drug development program
On Apr. 16, 2020, Atossa Therapeutics announced a new drug development program called COVID-19 HOPE. The program used…
FDA approved initiation of Humanigen’s phase III study of lenzilumab in COVID-19 patients
On Apr. 15, 2020, Humanigen announced that U.S. Food and Drug Administration (FDA) had given permission to commence…
FDA authorized first-of-its-kind low-cost ventilator developed by University of Minnesota
On Apr. 15, 2020, the U.S. Food and Drug Administration (FDA) authorized the production and use of a…